About 5 per cent of follicular lymphoma (FL) cases are double‐hit (DH) lymphomas. Double‐hit follicular lymphoma (DHFL) cell lines can improve our understanding and drug development on FL. But there are only few DHFL cell lines. Here, we established a new MYC/BCL2  DHFL cell line, FL‐SJC. The cells were obtained from the hydrothorax of a patient with MYC/BCL2 DHFL and cultured for 140 passages in vitro. FL‐SJC cells demonstrated CD19⁺⁺, CD20⁺, CD22⁺⁺, HLA‐DR⁺, CD10⁺, CD38⁺, Lambda⁺ CD23^‐, CD5^‐ and Kappa^‐. The chromosome karyotypic analysis confirmed the co‐existence of t(8;22)(q24;q11) and t(14;18)(q32;q21), as well as additional abnormalities involving chromosomes 2 and 3. Fluorescence in situ hybridization analysis (FISH) showed IGH/BCL2 fusion gene and the MYC rearrangement. In addition, the FL‐SJC cells displayed KMT2D/MLL2 and CREBBP gene mutations. After subcutaneous inoculation of FL‐SJC cells, the SCID mice developed solid tumour masses within 6‐8 weeks. FL‐SJC cells were proven to be free of Epstein‐Barr (EB) virus infection and be multidrug‐resistant. In a conclusion, the FL‐SJC cell line has been identified as a novel MYC/BCL2 double‐hit follicular lymphoma that can be used as a potentially available tool for the clinical and basic research, together with the drug development for MYC/BCL2 DHFL.

中文翻译：

---

新型“双击”滤泡性淋巴瘤细胞系FL-SJC的建立和表征。

滤泡性淋巴瘤（FL）病例中约有5％是双发（DH）淋巴瘤。双重打击滤泡性淋巴瘤（DHFL）细胞系可以增进我们对FL的了解和药物开发。但是仅有很少的DHFL细胞系。在这里，我们建立了一个新的MYC / BCL2  DHFL细胞系FL‐SJC。该细胞获自患有MYC / BCL2 DHFL的患者的胸膜，并在体外培养140代。FL-SJC细胞表现CD19 ⁺⁺，CD20 ⁺，CD22 ⁺⁺，HLA-DR ⁺，CD10 ⁺，CD38 ⁺，λ- ⁺ CD23 ^-，CD5 ^-和卡伯^-。染色体核型分析证实了t（8; 22）（q24; q11）和t（14; 18）（q32; q21）的共存，以及涉及染色体2和3的其他异常。荧光原位杂交分析（FISH）显示了IGH / BCL2融合基因和MYC重排。此外，FL‐SJC细胞还显示出KMT2D / MLL2和CREBBP基因突变。皮下接种FL‐SJC细胞后，SCID小鼠在6至8周内出现实体瘤。事实证明，FL‐SJC细胞不含爱泼斯坦·巴尔（EB）病毒感染，并且具有多药耐药性。总之，FL‐SJC细胞系已被鉴定为新型MYC / BCL2双发性滤泡性淋巴瘤可作为临床和基础研究的潜在工具，以及MYC / BCL2 DHFL的药物开发方法。